Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST) is a critical enzyme that serves as the E2 subunit of the alpha-ketoglutarate dehydrogenase complex (KGDHC). Located primarily in the mitochondrial matrix, DLST catalyzes the conversion of alpha-ketoglutarate to succinyl-CoA, a key step in the tricarboxylic acid (TCA) cycle that generates NADH to fuel oxidative phosphorylation (OXPHOS). Beyond its metabolic role, a small fraction of DLST localizes to the nucleus, where it participates in histone succinylation. DLST has emerged as a promising therapeutic target in oncology, as its overexpression or amplification is associated with poor prognosis and aggressive phenotypes in neuroblastoma, triple-negative breast cancer (TNBC), and ovarian cancer. Inhibiting DLST or its complex disrupts mitochondrial energy production, leading to tumor growth arrest and apoptosis. Devimistat (CPI-613) is a lipoate analog that functionally inhibits DLST lipoylation and KGDHC activity, and is currently being evaluated in clinical trials for various malignancies.
Inhibition of dihydrolipoamide S-succinyltransferase lipoylation, leading to the disruption of the alpha-ketoglutarate dehydrogenase complex (KGDHC) activity and subsequent inhibition of the mitochondrial tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST).